Literature DB >> 2146964

Interaction of fluoxetine with the human placental serotonin transporter.

D R Cool1, F H Liebach, V Ganapathy.   

Abstract

The interaction of fluoxetine, a non-tricyclic antidepressant, with the human placental serotonin transporter was investigated by studying its influence on [3H]paroxetine binding to the transporter and on [3H]serotonin uptake via the transporter. These studies were done using brush-border membrane vesicles purified from normal term human placentas. Fluoxetine inhibited binding of paroxetine to the membrane vesicles in a concentration-dependent manner, with a Ki value of 3 nM. Kinetic analysis revealed that the inhibition was competitive because the presence of 10 nM fluoxetine increased the Kd for paroxetine from 72 to 461 pM, but had no effect on the Bmax. Fluoxetine also caused a time-dependent dissociation of paroxetine already bound to the transporter. The dissociation followed first-order kinetics. Uptake of serotonin in these membrane vesicles was also inhibited by fluoxetine. The inhibition was concentration dependent with a Ki value of 66 nM at pH 7.5 and 80 nM at pH 6.5. The effect of fluoxetine on the uptake kinetics was to increase the apparent dissociation constant (Kt) for serotonin without influencing the maximal transport capacity (Vmax). The results demonstrate that fluoxetine is a high-affinity ligand and a potent inhibitor of the serotonin transporter found in the human placental brush-border membrane.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146964     DOI: 10.1016/0006-2952(90)90249-k

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Reconstitution of the human placental 5-hydroxytryptamine transporter in a catalytically active form after detergent solubilization.

Authors:  S Ramamoorthy; D R Cool; F H Leibach; V B Mahesh; V Ganapathy
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

2.  Disrupted placental serotonin synthetic pathway and increased placental serotonin: Potential implications in the pathogenesis of human fetal growth restriction.

Authors:  Suveena Ranzil; Stacey Ellery; David W Walker; Cathy Vaillancourt; Nadia Alfaidy; Alexander Bonnin; Anthony Borg; Euan M Wallace; Peter R Ebeling; Jan Jaap Erwich; Padma Murthi
Journal:  Placenta       Date:  2019-05-23       Impact factor: 3.481

Review 3.  The Placental Barrier: the Gate and the Fate in Drug Distribution.

Authors:  Nino Tetro; Sonia Moushaev; Miriam Rubinchik-Stern; Sara Eyal
Journal:  Pharm Res       Date:  2018-02-23       Impact factor: 4.200

4.  Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay.

Authors:  Rebecca A Harrington; Li-Ching Lee; Rosa M Crum; Andrew W Zimmerman; Irva Hertz-Picciotto
Journal:  Pediatrics       Date:  2014-04-14       Impact factor: 7.124

Review 5.  Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders.

Authors:  Leif Hertz; Dan Song; Baoman Li; Ting Du; Junnan Xu; Li Gu; Ye Chen; Liang Peng
Journal:  J Signal Transduct       Date:  2014-02-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.